2014 Oncology Literature Reviews Hematologic Malignancies Third Quarter

On a quarterly schedule, this online review series summarizes the information from key articles published in the JCO, as well as other major journals.  Articles selected for review will focus on translational science and clinical trial findings that are practice changing.  Pertinent Editorials and reviews may also be included when appropriate.

Learning Objectives

  • Review the recent shift in treatment away from chemoimmunotherapy in the initial treatment of chronic lymphocytic leukemia (CLL)
  • Examine the role of Lenalidomide in the up-front treatment of CLL
  • Discuss the role of BTK inhibition as a therapeutic strategy to treat relapsed and refractory CLL
  • Apply the findings in these articles to treat patients with newly diagnosed and relapsed CLL

 Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted. 
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes

  • This course expires on September 24, 2017. Participants must complete all necessary course components by this date to receive credit.